Pembrokeshire women make history in record-breaking Atlantic row
A team of four women from Pembrokeshire have made history by completing an extraordinary Atlantic row in just 53 days.
Their inspiring 3.200-mile journey from Lanzarote to Antigua has shattered two world records and raised over £20,000 for charity.
Janine Williams,70, is now the oldest woman in the world to row an ocean, while Sophie Pierce (32) has become the first person with Cystic Fibrosis to achieve this feat.
Alongside teammates Polly Zipperlen, 50, and Miyah Periam, 24, the women – all members of Neyland Rowing Club – battled relentless waves, sleep deprivation, and the extreme physical and mental challenges of ocean rowing to complete the challenge.
The 'Cruising Free' team arrived in Antigua on Thursday, March 27 – a week ahead of schedule – to be greeted by an emotional crowd of supporters, including family, friends, and fellow adventurers.
In their 10-metre rowing boat, Spirit of Bluestone, the team rowed in shifts around the clock, stopping only to eat together or shelter from four-metre waves. They survived on 1,000 dehydrated meals and relied on a water desalination machine, advanced communications, and a fridge to store Sophie's Cystic Fibrosis medication.
Social worker Sophie, from Johnston, said: 'If you had told me five years ago that I would be standing here in Antigua after rowing an ocean, I would have laughed.
"This journey has been incredibly tough, but also one of the most empowering experiences of my life.
"I hope this challenge not only inspires others with Cystic Fibrosis to push boundaries but also helps reimagine the future of CF."
For Janine, from Neyland, the row was a testament to the power of perseverance: "People kept asking if I was worried about rowing at 70, but I never doubted that we could do it," she said.
"This has been an adventure of a lifetime, proving that you're never too old to take on something extraordinary.'
Watersports instructor Miyah, from Milford Haven, added: 'This was harder than I ever imagined – but also more beautiful. The ocean is a wild, unpredictable place, but it has given us some of the most incredible moments of our lives.'
Polly Zipperlen, from Llangwm, added: "The ocean tested us in every way possible, but we kept each other going. We laughed, we cried, we sang our way through the hardest days – and we made it. This wasn't just about rowing; it was about proving what's possible when you work together and refuse to give up."
The team's challenge was also a mission to raise funds for three charities close to their hearts: the Cystic Fibrosis Trust, Paul Sartori Hospice at Home, and Emily's Entourage.
Donations can be made via the Cruising Free GoFundMe page.
was the team's key sponsor, and the company's chief executive, William McNamara, met them at the finish line in Antigua.
He said: 'What these women have accomplished is truly remarkable. Their determination and spirit embody everything we stand for at Bluestone, and we couldn't be prouder to have supported them on this journey.'
"Supporting this team on their journey has been an absolute privilege, and seeing them cross the finish line in Antigua was a moment I will never forget. Their story will inspire many, and we are incredibly proud to have been part of it."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Over 100 million at risk for daily severe storms, drenching rain into next week
A recent spate of severe weather to begin the month of June will persist for several more days. The storms are expected to impact an area encompassing over 100 million people east of the Rockies and interrupt outdoor plans for the weekend and beyond, warn AccuWeather meteorologists. The storminess, fueled mostly by hot summertime air, has led to hundreds of reports of wind damage, large hail and even a few tornadoes since the beginning of the month, spanning dozens of states. Many of the same areas reeling from recent severe weather will have to stay alert for additional storminess through at least Monday. "A series of low pressure areas moving into and then out of the Midwest through early next week will be the impetus for the successive severe weather risks from the Plains to the Southeast," said AccuWeather Senior Meteorologist Chad Merrill. The most recent storm led to reports of giant hail, hurricane-force winds and a few tornadoes across the southern Plains into Friday morning. Through the end of the week, this dangerous weather will build east across the Mississippi and Tennessee River valleys. Early weekend plans Saturday could be threatened across a large area spanning hundreds of miles from the U.S.-Mexico border to the mid-Atlantic coast. In addition to storms packing hailstones, destructive winds and always-dangerous lightning, heavy rain is a big concern, especially since storms will be repeating in many areas. "Besides the severe weather threat, repeated downpours will move over already-saturated soil," added Merrill. "Motorists will have to watch out for ponding of water on roads, and smaller creeks and streams will be susceptible to overflowing their banks." "Of particular concern for flooding is eastern Oklahoma into southern Kansas, including Wichita, which is already running a surplus of 2 to 5 inches of rain for early June," pointed out Merrill. At least three separate areas of severe weather are forecast to develop by Sunday across the Midwest, southern Plains and Southeast. Major cities such as Atlanta, Chicago, Dallas and St. Louis are at risk for these violent storms, which can also impact air travel nationwide because of the number of busy airport hubs in these storm-affected regions. The Red River Valley of Texas and Oklahoma appear to be at particular risk for dangerous storms to end the weekend, with AccuWeather meteorologists discussing the possibility of issuing a rare "high risk" for severe storms at some point in the near future. The severe threat will not end with the weekend, as the southern Plains and South are at "some' risk" for gusty storms by Monday, which will be, in some locales, the fourth consecutive day with a risk for severe weather. While wind, hail and heavy rain represent the primary threats from the storms, there have been a few tornado touchdowns over the last few days, and AccuWeather meteorologists are concerned for a few more during this episode of severe weather. "A couple of tornadoes can occur in the High Plains into Friday evening," warned Merrill. "On Saturday, the threat for tornadoes will shift south and east into the moderate risk area in the mid-South, between Interstates 20 and 40." Because of the vast amount of moisture in the atmosphere, any tornado that spawns could be enveloped in heavy rain and difficult to see. These are called rain-wrapped tornadoes, and they are especially dangerous after dark. With outdoor graduations and summer vacation plans getting underway, having a way to receive warnings both at and away from home or work will be important over the next few days. The AccuWeather App offers push notifications of severe weather alerts so you can take quick action in the event of storms. Want next-level safety, ad-free? Unlock advanced, hyperlocal severe weather alerts when you subscribe to Premium+ on the AccuWeather app. AccuWeather Alerts™ are prompted by our expert meteorologists who monitor and analyze dangerous weather risks 24/7 to keep you and your family safer.
Business Wire
2 days ago
- Business Wire
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year's European Cystic Fibrosis Society's (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit including better and more stable lung function, fewer pulmonary exacerbations, better nutritional status and better quality of life. SwCl levels below 30 mmol/L generally demonstrated greater numerical benefit than all other groups, with confidence intervals that overlapped with the ≥30 to <60 mmol/L group. Vertex also presented the results of a post hoc analysis from the Phase 3 randomized, controlled and open-label trials of ALYFTREK (abstract WS19.04) which suggest treatment with ALYFTREK is associated with improved health-related quality of life outcomes in adolescents and adults, and with improved CF symptoms and general functioning in children aged 6-11 years compared to patients treated with TRIKAFTA. 'These new data further demonstrate that reducing sweat chloride via treatment with CFTR modulators drives improved CFTR function and may ultimately result in better outcomes for patients across a variety of measures,' said Professor Isabelle Fajac, Pulmonologist, Professor of Physiology at APHP-Université Paris Cité, Paris, France. 'Importantly, the data also indicate that ALYFTREK, which has been shown to deliver even greater reductions in sweat chloride than TRIKAFTA, may drive improved quality of life and other health-related outcomes above and beyond even what we've seen with CFTR modulators to date.' About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 109,000 people, including 94,000 people in North America, Europe and Australia. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving. Today Vertex CF medicines are treating over 75,000 people with CF in more than 60 countries on six continents. This represents approximately 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy. In addition, we have established a pilot donation program in collaboration with Direct Relief to provide TRIKAFTA® to eligible people with CF in select lower-income countries. The program currently includes 14 countries across four continents. ABOUT ALYFTREK AND TRIKAFTA IN THE U.S. ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. * TRIKAFTA is indicated for the treatment of CF in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on clinical and/or in vitro data. * *If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of the indicated mutation(s) for the respective product. IMPORTANT SAFETY INFORMATION WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE Elevated transaminases have been observed in patients treated with ALYFTREK. TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in both clinical trials and the postmarketing setting in patients with and without a history of liver disease taking TRIKAFTA, a fixed-dose combination drug containing elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA), the same or similar active ingredients as ALYFTREK. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA. Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating ALYFTREK or TRIKAFTA, then every month during the first 6 months of treatment, every 3 months for the next 12 months, and at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or liver function test (LFT) elevations at baseline. Interrupt ALYFTREK or TRIKAFTA for significant elevations in LFTs or in the event of signs or symptoms of liver injury. Consider referral to a hepatologist. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If resolved, resume treatment only if benefit is expected to outweigh risk. Closer monitoring is advised after resuming treatment. ALYFTREK or TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C). ALYFTREK or TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced dosage and monitor patients closely. WARNINGS AND PRECAUTIONS DRUG-INDUCED LIVER INJURY AND LIVER FAILURE Elevated transaminases have been observed in patients treated with ALYFTREK. TRIKAFTA, which contains the same or similar active ingredients as ALYFTREK, can cause serious and potentially fatal drug-induced liver injury. Liver failure leading to transplantation and death has been reported in patients with and without a history of liver disease taking TRIKAFTA. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA Assess LFTs (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating ALYFTREK or TRIKAFTA, then every month during the first 6 months of treatment, every 3 months for the next 12 months, and at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or LFT elevations at baseline, or a history of elevated LFTs with drugs containing ELX, TEZ, and/or IVA Interrupt ALYFTREK or TRIKAFTA in the event of signs or symptoms of liver injury, which may include: Significant elevations in LFTs (e.g., ALT or AST >5x the upper limit of normal (ULN) or ALT or AST >3x ULN with bilirubin >2x ULN) Clinical symptoms suggestive of liver injury (e.g., jaundice, right upper quadrant pain, nausea, vomiting, altered mental status, ascites) Consider referral to a hepatologist and follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If resolved, and if benefit is expected to outweigh risk, resume treatment with close monitoring ALYFTREK and TRIKAFTA should not be used in patients with severe hepatic impairment. ALYFTREK and TRIKAFTA are not recommended in patients with moderate hepatic impairment and should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced dosage and monitor patients closely HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS Hypersensitivity reactions, including cases of angioedema and anaphylaxis, have been reported in the post marketing setting for TRIKAFTA. If signs or symptoms of serious hypersensitivity reactions develop during treatment, discontinue ALYFTREK or TRIKAFTA and institute appropriate therapy. Consider benefits and risks for the individual patient to determine whether to resume treatment PATIENTS WHO DISCONTINUED OR INTERRUPTED ELX-, TEZ-, OR IVA-CONTAINING DRUGS DUE TO ADVERSE REACTIONS ALYFTREK There are no available safety data for ALYFTREK in patients who previously discontinued or interrupted treatment with drugs containing ELX, TEZ, or IVA due to adverse reactions. Consider the benefits and risks before using ALYFTREK in these patients. If ALYFTREK is used in these patients, closely monitor for adverse reactions as clinically appropriate DRUG INTERACTIONS Use With CYP3A Inhibitors Exposure to vanzacaftor, tezacaftor, and deutivacaftor, or elexacaftor, tezacaftor, and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. The dose of ALYFTREK or TRIKAFTA should be reduced when used concomitantly with moderate or strong CYP3A inhibitors Use With CYP3A Inducers Following concomitant use of strong or moderate CYP3A inducers with ALYFTREK, exposures of vanzacaftor, tezacaftor, and deutivacaftor were decreased, which may reduce ALYFTREK effectiveness. Concomitant use with strong or moderate CYP3A inducers is not recommended Exposure to ivacaftor is significantly decreased and exposure to elexacaftor and tezacaftor are expected to decrease by concomitant use with CYP3A inducers, which may reduce therapeutic effectiveness of TRIKAFTA. Concomitant use with strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St. John's wort, is not recommended CATARACTS Non-congenital lens opacities/cataracts have been reported in pediatric patients treated with TRIKAFTA, which contain ivacaftor (similar to an active ingredient in ALYFTREK). Baseline and follow-up ophthalmological examinations are recommended in pediatric patients initiating treatment ADVERSE REACTIONS ALYFTREK Serious adverse reactions that occurred more frequently with ALYFTREK than with ELX/TEZ/IVA in 2 or more patients (≥0.4%) were influenza (1.5%), increased AST (0.4%), increased GGT (0.4%), depression (0.4%), and syncope (0.4%) The most common adverse reactions occurring in ≥5% of patients and at a frequency higher than ELX/TEZ/IVA by ≥1% were cough, nasopharyngitis, upper respiratory tract infection, headache, oropharyngeal pain, influenza, fatigue, increased ALT, rash, increased AST, and sinus congestion TRIKAFTA Serious adverse reactions that occurred more frequently in patients treated with TRIKAFTA compared to placebo included rash (1% vs <1%) and influenza (1% vs 0%) The most common adverse reactions occurring in ≥5% of patients treated with TRIKAFTA and at a rate higher than placebo by ≥1% were headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, blood bilirubin increased, and constipation USE IN SPECIFIC POPULATIONS PEDIATRIC USE Safety and effectiveness have not been established for ALYFTREK in patients younger than 6 years of age, nor for TRIKAFTA in patients younger than 2 years of age. The use in children under these ages is not recommended Please see full Prescribing Information, including Boxed Warning, for Alfytrek and Trikafta. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Professor Isabelle Fajac, in this press release, and statements regarding Vertex's beliefs about the potential benefits of ALYFTREK and TRIKAFTA for people with CF, and expectations for the pilot donation program. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, the risks listed under the heading 'Risk Factors' in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN)
CBS News
4 days ago
- CBS News
South Florida gets break from wet weather, heat and humidity return
After days of downpours, South Florida is finally enjoying a break from the wet weather. Thursday will be mainly dry with only a 10% chance of rain. Saharan dust is bringing drier air and lowering the chance of rain, it's also leading to some hazy conditions. The air quality will be lower due to the dust and anyone with respiratory conditions should try and limit their time outside. "Feels like" temps in the afternoon approach triple digits. NEXT Weather The rain has moved out and now the heat and humidity are back. It was a warm start to Thursday with temperatures in the low to mid 80s. Afternoon highs will rise to the upper 80s with filtered sunshine. It will feel like the upper 90s and the 100s when the humidity is factored in. There is a high risk of rip currents along the Atlantic beaches. Small craft should exercise caution over the Atlantic waters, however, there are no alerts or advisories for boaters in the Florida Keys. Chance of rain slowly increases over weekend and early next week. NEXT Weather On Friday, spotty showers will be possible but the chance of rain remains low. Highs will rise to around 90 degrees and it will feel like the upper 90s and 100s. The weekend will be a scorcher with highs soaring to the low 90s and heat indices in the triple-digits. Spotty afternoon storms will be possible. The chance of rain rises early to middle of next week with more showers and storms expected due to more moisture around.
